EyeGate public stock offering expected to generate $10 million

EyeGate Pharmaceuticals announced the pricing of a public offering of common stock and warrants that is expected to generate about $10 million, according to a press release.The underwritten public offering involves 1,176,470 shares of common stock and warrants to purchase up to 1,176,470 shares of common stock at a combined price of $8.50 per share of common stock and warrant to purchase one share of common stock.